Drug Profile
Research programme: polo-like kinase 1 inhibitors - Sareum
Latest Information Update: 28 Jul 2016
Price :
$50
*
At a glance
- Originator Sareum
- Class Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2016 No reports on development identified for Cancer in United Kingdom (unspecified route)
- 26 May 2010 Early research is ongoing in United Kingdom
- 20 Aug 2007 Early research in Cancer in United Kingdom (unspecified route)